171 related articles for article (PubMed ID: 21556724)
1. Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
Chang Y; Mbeo G; Littman SJ
J Gastrointest Cancer; 2012 Sep; 43(3):505-7. PubMed ID: 21556724
[TBL] [Abstract][Full Text] [Related]
2. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Bralet MP; Bellin MF; Guettier C; Adam R; Paule B
Clin Oncol (R Coll Radiol); 2006 Jun; 18(5):426. PubMed ID: 16817335
[No Abstract] [Full Text] [Related]
3. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
5. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
[TBL] [Abstract][Full Text] [Related]
8. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
Wang W; Zhao LR; Lin XQ; Feng F
World J Gastroenterol; 2014 Jun; 20(21):6691-7. PubMed ID: 24914397
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.
Rajasekhar A; George TJ
Oncologist; 2007 Nov; 12(11):1332-5. PubMed ID: 18055853
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.
Maeda T; Kikuchi E; Matsumoto K; Yazawa S; Hagiuda J; Miyajima A; Nakagawa K; Fujiwara H; Hoshino H; Oya M
Int J Clin Oncol; 2010 Oct; 15(5):508-11. PubMed ID: 20352464
[TBL] [Abstract][Full Text] [Related]
11. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin.
Sharief U; Perry DJ
Clin Colorectal Cancer; 2009 Jul; 8(3):163-5. PubMed ID: 19632931
[TBL] [Abstract][Full Text] [Related]
12. External beam radiation therapy with or without concurrent chemotherapy for patients with unresectable locally advanced hilar cholangiocarcinoma.
Chen SC; Chen MH; Li CP; Chen MH; Chang PM; Liu CY; Tzeng CH; Liu YM; Yen SH; Chao Y; Huang PI
Hepatogastroenterology; 2015; 62(137):102-7. PubMed ID: 25911877
[TBL] [Abstract][Full Text] [Related]
13. Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Marciano R; Servetto A; Bianco C; Bianco R
J Med Case Rep; 2017 Sep; 11(1):273. PubMed ID: 28946921
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
[TBL] [Abstract][Full Text] [Related]
15. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Wiazzane N; Chauffert B; Ghiringhelli F
Clin Res Hepatol Gastroenterol; 2013 Dec; 37(6):614-8. PubMed ID: 23711827
[TBL] [Abstract][Full Text] [Related]
17. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide.
Ryan SA; Maceneaney P; O'Reilly SP; Moylan EJ; Power DG
Med Oncol; 2012 Jun; 29(2):1287-91. PubMed ID: 21390516
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Lee MA; Woo IS; Kang JH; Hong YS; Lee KS
Jpn J Clin Oncol; 2004 Sep; 34(9):547-50. PubMed ID: 15466829
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
[TBL] [Abstract][Full Text] [Related]
20. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.
Levy CF; Oo KZ; Fireman F; Pierre L; Bania MA; Sadanandan S; Yamashiro DJ; Glade Bender JL
Pediatr Blood Cancer; 2009 May; 52(5):669-71. PubMed ID: 19101996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
